Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8486456 | SEBELA IRELAND LTD | Itraconazole compositions with improved bioavailability |
Oct, 2028
(5 years from now) |
Market Authorisation Date: 29 April, 2010
Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks
Dosage: TABLET;ORAL
3
United States
2
Japan
2
European Union
1
Spain
1
Canada
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8771739 | MAYNE PHARMA INTL | Pharmaceutical compositions for poorly soluble drugs |
Jul, 2023
(4 months from now) | |
US10463740 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
US8921374 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
US9272046 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
US9713642 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
US10806792 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) |
Market Authorisation Date: 11 December, 2018
Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis
Dosage: CAPSULE;ORAL
11
United States
9
Australia
4
Japan
3
Korea, Republic of
3
European Union
2
Canada
2
China
1
Portugal
1
Hong Kong
1
Mexico
1
Spain
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic